Belite Bio Completes Enrollment in Phase 3 Stargardt Disease Trial for Tinlarebant

Belite Bio (NASDAQ: BLTE) announced on January 27, 2026, the completion of patient enrollment in its Phase 3 DRAGON II clinical trial evaluating oral drug tinlarebant for Stargardt disease, a genetic eye disorder. The milestone keeps the trial on track for topline data readout in early 2027. The global study enrolled 66 patients aged 12-18 across multiple regions. Tinlarebant is designed to slow vision loss by reducing toxic vitamin A derivatives in the retina. Positive results could support regulatory submissions in key markets and address a significant unmet medical need with no currently approved therapies.